melanoma

15 · 20 / page

Ask MedXY AI

Latest news

Tag

Dermatologyinsurance disparitiesmelanoma

Exploring Institutional and Insurance-Linked Disparities in Melanoma Outcomes: Insights from a VA and Tertiary Care Cohort Study

By MedXY|Jul 14, 2026

This cohort study reveals differential melanoma survival outcomes linked to institutional settings and insurance types, highlighting the need for standardized care in advanced melanoma stages.

Immune Checkpoint Inhibitor-Associated Uveitis: Comparative Risk Across Cancers and Drug Classes

newsimmune checkpoint inhibitors

melanoma

Latest news

Exploring Institutional and Insurance-Linked Disparities in Melanoma Outcomes: Insights from a VA and Tertiary Care Cohort Study

Immune Checkpoint Inhibitor-Associated Uveitis: Comparative Risk Across Cancers and Drug Classes

Breaking the Wall: Can Intermittent Chemotherapy Overcome Primary Checkpoint Inhibitor Resistance in Metastatic Melanoma?

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients

Nivolumab Redefines Long-Term Outcomes in Resected High-Risk Melanoma: 9-Year Insights from CheckMate 238

Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma

Routine Whole‑Body Imaging Did Not Improve Early Survival in High‑Risk Melanoma: Interim TRIM Trial Analysis

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

Refining Sentinel Lymph Node Biopsy Decisions in Melanoma: Insights from the MERLIN_001 Gene Expression Profiling Study

Enhancing Melanoma Prognosis: AI-Driven Quantification of Tumor-Infiltrating Lymphocytes Outperforms Traditional Pathology

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives

Bridging the Gap: Overcoming Barriers to Timely Melanoma Diagnosis and Treatment in Latino Patients

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

It’s Melanoma — Here’s What to Do Next

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma